Anti-NMDA receptor encephalitis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(One intermediate revision by the same user not shown)
Line 4: Line 4:


==Overview==
==Overview==
The treatment of anti-NMDAR encephalitis involves immunotherapy, tumor diagnosis, and excision. Early immunotherapy has shown to improve outcomes. Treatment options include corticosteroids, plasmapheresis, immunoglobulins, and rituximab.


==Medical Therapy==
==Medical Therapy==
Line 15: Line 16:
[[Category:Rheumatology]]
[[Category:Rheumatology]]
[[Category:Disease]]
[[Category:Disease]]
 
<ref name="pmid18851928">{{cite journal| author=Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M | display-authors=etal| title=Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. | journal=Lancet Neurol | year= 2008 | volume= 7 | issue= 12 | pages= 1091-8 | pmid=18851928 | doi=10.1016/S1474-4422(08)70224-2 | pmc=2607118 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18851928  }} </ref>
<ref name="pmid23946310">{{cite journal| author=Titulaer MJ, McCracken L, Gabilondo I, Iizuka T, Kawachi I, Bataller L | display-authors=etal| title=Late-onset anti-NMDA receptor encephalitis. | journal=Neurology | year= 2013 | volume= 81 | issue= 12 | pages= 1058-63 | pmid=23946310 | doi=10.1212/WNL.0b013e3182a4a49c | pmc=3795591 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23946310  }} </ref>
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 13:03, 13 May 2023

Anti-NMDA receptor encephalitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Anti-NMDA receptor encephalitis from Other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Anti-NMDA receptor encephalitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Anti-NMDA receptor encephalitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Anti-NMDA receptor encephalitis medical therapy

CDC on Anti-NMDA receptor encephalitis medical therapy

Anti-NMDA receptor encephalitis medical therapy in the news

Blogs on Anti-NMDA receptor encephalitis medical therapy

Directions to Hospitals Treating Anti-NMDA receptor encephalitis

Risk calculators and risk factors for Anti-NMDA receptor encephalitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] AE Dheeraj Makkar, M.D.[2]

Overview

The treatment of anti-NMDAR encephalitis involves immunotherapy, tumor diagnosis, and excision. Early immunotherapy has shown to improve outcomes. Treatment options include corticosteroids, plasmapheresis, immunoglobulins, and rituximab.

Medical Therapy

The treatment of anti-NMDAR encephalitis should include immunotherapy and the diagnosis and excision of the tumor.  There is evidence that early immunotherapy may result in quicker recovery and decreased mortality.

Current immunotherapy includes corticosteroids, immune plasmapheresis, intravenous immunoglobulins, and rituximab.

References

[1] [2] Template:WH Template:WS

  1. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M; et al. (2008). "Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies". Lancet Neurol. 7 (12): 1091–8. doi:10.1016/S1474-4422(08)70224-2. PMC 2607118. PMID 18851928.
  2. Titulaer MJ, McCracken L, Gabilondo I, Iizuka T, Kawachi I, Bataller L; et al. (2013). "Late-onset anti-NMDA receptor encephalitis". Neurology. 81 (12): 1058–63. doi:10.1212/WNL.0b013e3182a4a49c. PMC 3795591. PMID 23946310.